The dynamics of the diffuse cutaneous systemic sclerosis market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies.
LAS VEGAS, Oct. 5, 2023 /PRNewswire/ -- DelveInsight's Diffuse Cutaneous Systemic Sclerosis Market Insights report includes a comprehensive understanding of current treatment practices, diffuse cutaneous systemic sclerosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Diffuse Cutaneous Systemic Sclerosis Market Report
- According to DelveInsight analysis, the diffuse cutaneous systemic sclerosis market is anticipated to increase at a significant CAGR during the forecast period due to the expected launch of emerging therapies.
- According to Orphanet (2021), the prevalence of diffuse cutaneous systemic sclerosis is estimated at about 1/25,000 adults and women are predominantly affected F/M sex ratio around 4:1.
- Globally, leading diffuse cutaneous systemic sclerosis companies such as Kadmon Corporation, Kyowa Kirin Co., Ltd., Gesynta Pharma AB, Acceleron Pharma Inc, Mitsubishi Tanabe Pharma Development, Emerald Health Pharmaceuticals, Cumberland Pharmaceuticals, Horizon Therapeutics Ireland DAC, CSL Behring, Seagen Inc., Janssen Pharmaceutical, Prometheus Biosciences, Inc., GlaxoSmithKline, Certa Therapeutics, and others are developing novel diffuse cutaneous systemic sclerosis drugs that can be available in the diffuse cutaneous systemic sclerosis market in the coming years.
- Some key therapies for diffuse cutaneous systemic sclerosis treatment include KD025/Belumosudil, KHK4827, GS-248, ACE-1334, MT-0551, EHP-101, Vasculan (ifetroban), MT-7117, HZN-825, IgPro20, Brentuximab Vedotin, Guselkumab, PRA023 IV, Belimumab and Rituximab, FT011, Guselkumab, and others.
Discover which therapies are expected to grab the major diffuse cutaneous systemic sclerosis market share @ Diffuse Cutaneous Systemic Sclerosis Market Report
Diffuse Cutaneous Systemic Sclerosis Overview
Diffuse cutaneous systemic sclerosis (dcSSc) is a medical condition characterized by widespread skin hardening and complications in multiple organs throughout the body. This fibrosis often affects the skin of the arms, both above and below the elbows, and frequently extends to the legs, both above and below the knees. In some cases, the face may also be involved. While this condition can manifest at any age, it is most commonly diagnosed in individuals between 40 and 50 years old. Symptoms of dcSSc include Raynaud's phenomenon, progressive skin fibrosis initially localized to the fingers and face but eventually spreading across the body, presence of "spider veins" on the chest, face, lips, tongue, and fingers, gastroesophageal reflux, difficulty swallowing, often leading to weight loss, vomiting, diarrhea, or constipation, and dry mouth and potential dental complications.
Diagnosis typically relies on the characteristic clinical presentation and the presence of specific microangiopathy observed during nailfold capillaroscopy. While skin biopsy is generally unnecessary, essential blood tests are required. Antitopoisomerase autoantibodies are detectable in approximately 30-40% of cases. To assess the disease's extent, medical professionals often employ a combination of computed tomography, electrocardiography, echocardiography, hand radiography, and, when necessary, esophageal and gastric fibroscopy.
Diffuse Cutaneous Systemic Sclerosis Epidemiology Segmentation
The diffuse cutaneous systemic sclerosis epidemiology section provides insights into the historical and current diffuse cutaneous systemic sclerosis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The diffuse cutaneous systemic sclerosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Diffuse Cutaneous Systemic Sclerosis Prevalent Cases
- Diffuse Cutaneous Systemic Sclerosis Gender-specific Cases
Diffuse Cutaneous Systemic Sclerosis Treatment Market
While there are various treatment options available, no curative treatment has been identified thus far. Current therapies primarily aim to delay disease progression rather than prevent severe complications. According to the EULAR treatment recommendations from 2016, therapeutic choices for diffuse cutaneous systemic sclerosis include methotrexate, cyclophosphamide, mycophenolate mofetil, and, in specific cases, autologous stem cell transplantation. It is essential to explore alternative outcome measures in future research to potentially provide a more comprehensive assessment of treatment effectiveness.
Tumor necrosis factor (TNF) inhibitors are a class of medications designed to combat inflammation and are employed in the treatment of DcSSc. These inhibitors include infliximab, adalimumab, etanercept, and rituximab. They can be administered either individually or in conjunction with other drugs such as prednisone, methotrexate, hydroxychloroquine, leflunomide, or sulfasalazine.
Proton pump inhibitors (PPIs) are commonly used to alleviate the symptoms of reflux esophagitis, which are nearly ubiquitous in systemic sclerosis. To address delayed gastric emptying, dopamine receptor antagonists like metoclopramide or domperidone can be employed. In the case of diffuse cutaneous systemic sclerosis (dcSSc), medications such as omeprazole, pantoprazole, and rabeprazole from the PPI class are utilized.
To know more about diffuse cutaneous systemic sclerosis treatment, visit @ Diffuse Cutaneous Systemic Sclerosis Treatment Drugs
Key Diffuse Cutaneous Systemic Sclerosis Therapies and Companies
- KD025/Belumosudil: Kadmon Corporation
- KHK4827: Kyowa Kirin Co., Ltd.
- GS-248: Gesynta Pharma AB
- ACE-1334: Acceleron Pharma Inc
- MT-0551: Mitsubishi Tanabe Pharma Development
- EHP-101: Emerald Health Pharmaceuticals
- Vasculan (ifetroban): Cumberland Pharmaceuticals
- MT-7117: Mitsubishi Tanabe Pharma Development
- HZN-825: Horizon Therapeutics Ireland DAC
- IgPro20: CSL Behring
- Brentuximab Vedotin: Seagen Inc.
- Guselkumab: Janssen Pharmaceutical
- PRA023 IV: Prometheus Biosciences, Inc.
- Belimumab and Rituximab: GlaxoSmithKline
- FT011: Certa Therapeutics
- Guselkumab: Janssen Pharmaceutical
Learn more about the FDA-approved drugs for diffuse cutaneous systemic sclerosis @ Drugs for Diffuse Cutaneous Systemic Sclerosis Treatment
Diffuse Cutaneous Systemic Sclerosis Market Dynamics
The diffuse cutaneous systemic sclerosis market dynamics are expecte to change in the coming years. In case studies, intravenous immunoglobulin, anti-TNF-α, and anti-IL-17 biologics, along with other repurposed biologics like IL-12/IL-23 and IL-4Rα neutralizing antibodies, have demonstrated clinical benefits. The establishment of a National Registry for Ichthyosis aims to facilitate the search for fundamental defects, enhance diagnostic methods, and develop more effective treatments and prevention strategies. Moreover, current therapies are expensive and demand extensive time commitments from both patients and their caregivers, who devote a substantial portion of their day to skin care. In addition, presently, there is no validated, standardized scoring system available to assess the severity of the disease. Thus, these factors will propel the diffuse cutaneous systemic sclerosis market during the forecast period.
However, several factors may impede the growth of the diffuse cutaneous systemic sclerosis market. Given the extreme rarity of this disease, there is a dearth of available literature. Individuals afflicted with diffuse cutaneous systemic sclerosis require routine check-ups due to the frequent recurrence of the disease. Moreover, the medications used in its treatment come with potentially severe side effects. To compound matters, most of the promising drug candidates are still in the preclinical stages of development, meaning patients may have to wait a bit longer for the introduction of novel treatments.
Report Metrics | Details |
Study Period | 2019–2032 |
Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Key Diffuse Cutaneous Systemic Sclerosis Companies | Kadmon Corporation, Kyowa Kirin Co., Ltd., Gesynta Pharma AB, Acceleron Pharma Inc, Mitsubishi Tanabe Pharma Development, Emerald Health Pharmaceuticals, Cumberland Pharmaceuticals, Horizon Therapeutics Ireland DAC, CSL Behring, Seagen Inc., Janssen Pharmaceutical, Prometheus Biosciences, Inc., GlaxoSmithKline, Certa Therapeutics, and others |
Key Diffuse Cutaneous Systemic Sclerosis Therapies | KD025/Belumosudil, KHK4827, GS-248, ACE-1334, MT-0551, EHP-101, Vasculan (ifetroban), MT-7117, HZN-825, IgPro20, Brentuximab Vedotin, Guselkumab, PRA023 IV, Belimumab and Rituximab, FT011, Guselkumab, and others |
Scope of the Diffuse Cutaneous Systemic Sclerosis Market Report
- Therapeutic Assessment: Diffuse Cutaneous Systemic Sclerosis current marketed and emerging therapies
- Diffuse Cutaneous Systemic Sclerosis Market Dynamics: Conjoint Analysis of Emerging Diffuse Cutaneous Systemic Sclerosis Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Diffuse Cutaneous Systemic Sclerosis Market Access and Reimbursement
Discover more about diffuse cutaneous systemic sclerosis drugs in development @ Diffuse Cutaneous Systemic Sclerosis Clinical Trials
Table of Contents
1. | Diffuse Cutaneous Systemic Sclerosis Market Key Insights |
2. | Diffuse Cutaneous Systemic Sclerosis Market Report Introduction |
3. | Diffuse Cutaneous Systemic Sclerosis Market Overview at a Glance |
4. | Diffuse Cutaneous Systemic Sclerosis Market Executive Summary |
5. | Disease Background and Overview |
6. | Diffuse Cutaneous Systemic Sclerosis Treatment and Management |
7. | Diffuse Cutaneous Systemic Sclerosis Epidemiology and Patient Population |
8. | Patient Journey |
9. | Diffuse Cutaneous Systemic Sclerosis Marketed Drugs |
10. | Diffuse Cutaneous Systemic Sclerosis Emerging Drugs |
11. | Seven Major Diffuse Cutaneous Systemic Sclerosis Market Analysis |
12. | Diffuse Cutaneous Systemic Sclerosis Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Unmet Needs |
16. | SWOT Analysis |
17. | Appendix |
18. | DelveInsight Capabilities |
19. | Disclaimer |
20. | About DelveInsight |
Related Reports
Diffuse Cutaneous Systemic Sclerosis Epidemiology
Diffuse Cutaneous Systemic Sclerosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted diffuse cutaneous systemic sclerosis epidemiology in the 7MM.
Diffuse Cutaneous Systemic Sclerosis Pipeline
Diffuse Cutaneous Systemic Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diffuse cutaneous systemic sclerosis companies, including Kadmon Pharmaceuticals, Talaris Therapeutics, Horizon Therapeutics, Mitsubishi Tanabe Pharma, Takeda Oncology, Seagen, among others.
Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key systemic sclerosis companies, including Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Pfizer, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences, among others.
Systemic Sclerosis-associated Interstitial Lung Disease Market
Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key systemic sclerosis-associated interstitial lung disease companies, including Boehringer Ingelheim Pharmaceuticals, Roche, Acceleron Pharma, Talaris Therapeutics, Kadmon Corporation, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:
Voltar noticias em Inglês